NDPS Notifications October 2026- New Drug Classifications and Quantity Limits
Quick note
Below is the official summary and the reference document preview. Use “Open PDF” for full screen view.
Schedule a Call Back
Businesses we've worked with on drug licence
Clients include Cure and Care Wellness, 1008 Digital Health, Nfilade Security Solutions, Evoq Technologies, Kantika Import Export and Trading, Rock Well Industries, Abhay Healthtech, Hind Svasthya Healthcare, Pridus Global Pharma, Arka Brenstech, Believe Cosmetics, Imedicndr Healthcare (12 of 40+ served since 2018).
A few more clients we've served in this industryHide the list
- Clients include
- Cure and Care Wellness · 1008 Digital Health · Nfilade Security Solutions · Evoq Technologies · Kantika Import Export and Trading · Rock Well Industries · Abhay Healthtech · Hind Svasthya Healthcare · Pridus Global Pharma · Arka Brenstech · Believe Cosmetics · Imedicndr Healthcare · Katre Enterprises · Soapsquare Healthcare · Xsourcee
Summary
Three notifications have been made by the Ministry of Finance, Department of Revenue, under the NDPS Act, 1985, on 28 October 2026. The government has notified two such substances as manufactured drugs, while MDMB-FUBINACA has been added to the category of psychotropic substances along with quantity limits.
The changes are relevant to businesses, research organisations and laboratories that handle these substances. They also establish quantity thresholds used when applying certain provisions of the NDPS Act.
The notifications do not introduce a general registration requirement for every pharmaceutical or chemical business. Their impact depends on the substance involved and the nature of the activity.
Notification at a Glance
| Particular | Details |
| Issuing Authority | Ministry of Finance, Department of Revenue |
| Notification Date | 28 October 2026 |
| Gazette Publication Date | 28 October 2026 |
| Notification Numbers | S.O. 5866(E), S.O. 5867(E), S.O. 5868(E) |
| Applicable Law | Narcotic Drugs and Psychotropic Substances Act, 1985 |
| Main Changes | Classification of manufactured drugs, amendment to the psychotropic substances Schedule and notification of quantity thresholds |
| Substances Covered | N-pyrrolidino isotonitazene, N-desethyl etonitazene and MDMB-FUBINACA |
| Effective Date | S.O. 5866(E) and S.O. 5868(E) expressly take effect upon Gazette publication. S.O. 5867(E) was published on the same Date but contains no separate commencement clause |
| Gazette Reference | CG-DL-E-28102026-277480 |
| Jurisdiction | India |
The Regulatory Framework Under the NDPS Act, 1985
The Narcotic Drugs and Psychotropic Substances Act, 1985, regulates activities involving narcotic drugs and psychotropic substances in India. It covers matters such as production, manufacture, possession, sale, purchase, transport, use and cross-border movement.
Section 8 of the Act places restrictions on these activities. Activities permitted for medical or scientific purposes must comply with the applicable provisions of the Act, Rules and any required licence, permit or authorisation. The government can also bring additional substances within the regulatory framework through notifications published in the Official Gazette.
Several provisions are relevant to the October 2026 changes:
- Section 2(xi)(b): Allows the Central Government to declare specified narcotic substances or preparations as manufactured drugs.
- Section 3: Empowers the Central Government to add or remove substances from the Schedule of psychotropic substances.
- Section 2(viia): Defines commercial quantity by reference to the figure notified by the government.
- Section 2(xxiiia): Defines small quantity by reference to the figure notified by the government.
The small and commercial quantity figures are maintained through S.O. 1055(E), dated 19 October 2001, and its subsequent amendments.
The notifications issued on 28 October 2026 use these existing legal powers. They change the status of specified substances and add quantity entries they do not replace the NDPS Act or introduce a new regulatory framework.
What Has Changed Under the NDPS Notifications of 28 October 2026?
The government has made three separate changes. Although they were published together, each notification serves a different legal purpose.
Declaration of Two Manufactured Drugs
Through S.O. 5866(E), the government has declared N-pyrrolidino isotonitazene (Isotonitazepyne) and N-desethyl etonitazene to be manufactured drugs under Section 2(xi)(b) of the NDPS Act.
The declaration also refers to their salts and preparations. It follows the government's consideration of decisions under the United Nations Single Convention on Narcotic Drugs, 1961. The notification expressly came into force on publication in the Official Gazette on 28 October 2026.
Addition of MDMB-FUBINACA to the Psychotropic Substances Schedule
Through S.O. 5867(E), MDMB-FUBINACA has been included in the Schedule of psychotropic substances under the NDPS Act. The substance has been inserted at serial number 110ZZL, immediately after entry 110ZZK. The notification refers to available evidence concerning the substance and developments under the United Nations Convention on Psychotropic Substances, 1971.
Introduction of New Small and Commercial Quantity Limits
Through S.O. 5868(E), the government has added three entries to the existing notification specifying small and commercial quantities. The new entries establish separate numerical limits for each of the three substances. These figures matter when the applicable NDPS provisions require a distinction between offences involving small quantities, quantities between the notified limits and commercial quantities.
How Do the Three NDPS Notifications of October 2026 Differ?
The main difference is that the first two notifications concern legal classification, while the third concerns quantity thresholds.
| Notification | Legal Basis | Main Change | Substances Covered |
| S.O. 5866(E) | Section 2(xi)(b) | Declares substances to be manufactured drugs | Isotonitazepyne and N-desethyl etonitazene |
| S.O. 5867(E) | Section 3 | Adds a substance to the psychotropic substances Schedule | MDMB-FUBINACA |
| S.O. 5868(E) | Sections 2(viia) and 2(xxiiia) | Specifies small and commercial quantity figures | All three substances |
The three notifications should therefore be read together but not treated as interchangeable.
For example, the manufactured-drug declaration establishes the legal classification of the two named substances. The separate quantity notification establishes the numerical figures relevant to quantity-based provisions.
Similarly, the inclusion of MDMB-FUBINACA in the psychotropic substances Schedule is a classification change, while its small and commercial quantity figures are specified separately.
Which Substances Have Been Added Under the NDPS Act in October 2026?
Three substances are covered by the October 2026 notifications, although they have not all been added to the same statutory Schedule.
N-Pyrrolidino Isotonitazene (Isotonitazepyne)
N-pyrrolidino isotonitazene, also identified as Isotonitazepyne, has been declared a manufactured drug under S.O. 5866(E). The Gazette provides its full chemical name to identify the substance precisely. Its new classification is particularly relevant when determining which statutory controls apply to activities involving it.
N-Desethyl Etonitazene
N-desethyl etonitazene is the second substance declared a manufactured drug through S.O. 5866(E).The government has notified this substance separately from Isotonitazepyne, with its own chemical identity and small and commercial quantity figures. Any organisation dealing with the substance should use the chemical identification given in the Gazette when reviewing its regulatory position.
MDMB-FUBINACA
MDMB-FUBINACA has been added to the Schedule of psychotropic substances under the NDPS Act through S.O. 5867(E). Its new entry number is 110ZZL.
This is important because the Act defines a psychotropic substance by reference to the substances and preparations included in its statutory Schedule.For laboratories and other relevant organisations, the exact identity of the substance is important when determining which legal provisions apply.
Difference Between Manufactured Drugs and Psychotropic Substances Under the NDPS Act
Manufactured drugs and psychotropic substances are both regulated under the NDPS framework, but they are not classified in the same way.
A manufactured drug is defined under Section 2(xi) of the NDPS Act. The definition includes certain specified narcotic drug categories as well as other substances or preparations declared manufactured drugs by the Central Government.
A psychotropic substance, under Section 2(xxiii), is a substance, natural or synthetic, natural material, salt or preparation included in the Schedule of psychotropic substances under the Act.
The distinction matters because the applicable permissions, restrictions and offence provisions may differ. For instance, manufacture of notified manufactured drugs is addressed under Rule 37 of the NDPS Rules, 1985, subject to its conditions and exclusions. Manufacturing psychotropic substances is addressed under Rule 64, which refers to licensing under the Drugs and Cosmetics Rules, 1945, together with additional conditions where applicable.
Another important distinction is that the Schedule to the NDPS Act and Schedule I to the NDPS Rules are separate legal lists. Inclusion in one must not automatically be described as inclusion in the other. Businesses should determine the correct classification before deciding which licence, approval or regulatory process may apply.
New Small and Commercial Quantity Limits Under the NDPS Notification 2026
One of the most significant parts of the October 2026 update is the specification of small and commercial quantity figures. Under S.O. 5868(E), the government has inserted the following entries into the quantity notification originally issued on 19 October 2001.
| Substance | Entry Number | Notified Small Quantity | Notified Commercial Quantity |
| N-pyrrolidino isotonitazene (Isotonitazepyne) | 238ZZZS | 0.0017 g | 0.085 g |
| N-desethyl etonitazene | 238ZZZT | 0.0005 g | 0.025 g |
| MDMB-FUBINACA | 238ZZZU | 0.0025 g | 0.125 g |
What Is Small Quantity Under the NDPS Act?
Section 2(xxiiia) defines small quantity by reference to a quantity lesser than the figure specified by the Central Government through notification. The figure notified for each substance is therefore important when applying provisions that distinguish offences according to quantity. However, a small quantity does not mean that an individual or business is legally permitted to possess that amount without satisfying the applicable law.
What Is Commercial Quantity Under the NDPS Act?
Section 2(viia) defines commercial quantity by reference to a quantity greater than the figure specified by the Central Government. The distinction can affect the application of statutory punishment provisions and other legal conditions associated with certain NDPS offences.
Definitions under the laws employ certain terminology when referring to amounts below or above those notified. In cases where there is an amount equivalent to those that have been notified, one should consider the statutory definition and interpretation thereof.
Why Do These Quantity Limits Matter?
Under the NDPS Act, the quantity involved can influence how particular offences are treated. The notified figures help establish which quantity-related statutory provisions may apply to the substance concerned.These limits do not establish permitted manufacturing volumes, approved storage capacity, allowable imports or trading entitlements.
Those matters must be assessed separately under the applicable provisions of the Act, Rules and any relevant authorisations.
Impact of the NDPS Notifications on Businesses and Organisations
The October 2026 notifications are not directed at every pharmaceutical manufacturer or chemical business. Their practical relevance depends on whether an organisation handles one of the named substances and what activities it undertakes.
Pharmaceutical and Chemical Operators
Businesses that manufacture or otherwise deal with any of the notified substances should examine their activities against the amended classifications.
An existing drug licence should not automatically be treated as sufficient for every activity governed by the NDPS Act. Where a specific NDPS permission or authorisation is required, that requirement must be considered separately.
Research Institutions and Testing Laboratories
Laboratories and research organisations may need to review how they identify, receive, possess, test and account for samples containing the notified substances. Any recordkeeping, possession or authorisation requirements must be determined from the applicable legal provisions rather than assumed solely from these notifications. The change is relevant where a facility actually handles one of the named substances.
Importers and Exporters
Those entities participating in the legal international dealings regarding narcotic drugs or psychotropic substances shall verify the relevant import and export control requirements. The CBND issues relevant import licenses and export permissions under the NDPS Rules.
The October 2026 notifications do not themselves establish a separate, universal import or export application process. The required permission depends on the substance, activity and applicable rules.
Legal Implications of the New NDPS Classifications and Quantity Limits
The legal implications of these notifications arise from how the new classifications and quantity entries interact with the existing NDPS Act.
Applicability of Existing Offence Provisions
Section 21 deals with specified contraventions involving manufactured drugs and their preparations. Section 22 addresses specified contraventions involving psychotropic substances.
Depending on the activity, other provisions may also apply. For instance, Section 23 addresses certain unlawful imports into India, exports from India and transhipments. The government has not introduced these offence provisions through the October 2026 notifications. They were already part of the statutory framework.
Quantity-Based Punishment Provisions
Sections 21 and 22 contain graded penalties for relevant offences according to the quantity involved.
Under these provisions:
- Small-quantity offences: Rigorous imprisonment of up to one year, or a fine of up to Rs 10,000, or both.
- Offences involving more than small quantity but less than commercial quantity: Rigorous imprisonment of up to ten years and a fine of up to Rs1 lakh.
- Commercial-quantity offences: Rigorous imprisonment of 10 to 20 years and a fine generally ranging from Rs1 lakh to Rs2 lakh. The court may impose a higher fine for reasons recorded in its judgment.
This is an example of existing statutory penalties, not newly created penalties that took effect on 28 October 2026. It all depends on the offence committed, the drug involved, the amount determined by law, and the facts of the case.
Importance of Accurate Substance Identification
The chemical identity of a substance and its treatment under the law can affect the applicable legal classification. For regulated businesses and laboratories, checking the correct chemical name, existing authorisations and relevant documentation is therefore important.
Where a material is a preparation or mixture, the applicable rules and judicial decisions concerning quantity determination may also need consideration. The three notifications should not be interpreted as creating a blanket prohibition on unrelated pharmaceutical products or business activities.
What Businesses Should Do Next
Businesses and organisations connected with the notified substances should review their regulatory position using the following checks.
1. Determine whether the substances are used.
Identify which of the three mentioned substances are being used in the activities conducted.
2. Verify the classification of the substance
Compare the chemical name with that published in the Gazette notification to verify if the substance is included in the manufactured drug declarations or Psychotropic substances Schedule entries.
3. Examine the permissions granted
Where there are licenses, permits or authorizations for an activity issued under the NDPS Act and Rules, see if the permission allows the use of the substance for the activity being conducted.
4. Review relevant records
Check the records required by the Rules or by the conditions of the license. Any other internal records may be considered useful but should not be called new legal requirements.
5. Determine import/export requirements
For those activities involving imports and exports, seek confirmation of the requirements from the competent authority.
6. Update internal compliance procedures where necessary
If the organisation handles one of the notified substances, it may be appropriate to update its internal substance lists, review procedures and staff guidance.
7. Clarify if the position is unclear
It is recommended that the businesses seek advice from the relevant authority or the suitable regulator where there are no clear answers for the proposed activity from any existing authorization or statutory requirement.
These are some practical considerations. There was nothing mentioned about a deadline or a need for re-registration by all drug businesses in the 2026 October notifications.
How Can Corpseed Help with Relevant Drug Licensing and Regulatory Compliance?
Businesses dealing with regulated pharmaceutical or chemical substances may need assistance in identifying the applicable licensing framework and preparing the relevant documents.
Corpseed provides published services relating to drug licence registration in India and CDSCO test licences. Their relevance depends on the applicant's activities and the permissions required.
Depending on the scope of the service, assistance may include:
- Applicability review: Understanding the proposed business activity and the relevant regulatory requirements.
- Documentation support: Identifying and preparing supporting documents for applicable licensing procedures.
- Application assistance: Supporting submissions within the scope of the company's published licensing services.
- Regulatory coordination: Helping applicants understand the documentation and approval process relevant to their case.
A drug licence or CDSCO test licence does not, by itself, replace any permission specifically required under the NDPS framework.
Need help reviewing drug licensing requirements? Contact Corpseed to discuss the activity, substances involved and relevant regulatory documentation before proceeding with an application.
Key Takeaways
- The Ministry of Finance issued three NDPS notifications on 28 October 2026.
- N-pyrrolidino isotonitazene and N-desethyl etonitazene have been declared manufactured drugs under S.O. 5866(E).
- MDMB-FUBINACA has been added to the psychotropic substances Schedule under S.O. 5867(E).
- S.O. 5868(E) specifies small and commercial quantity figures for all three substances.
- Organisations handling these substances should examine their applicable permissions and obligations under the NDPS Act and Rules.
Schedule a Call Back
Document Preview
Embedded reference document
